๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Follicular Lymphoma (FL)
Clinical trial register · China

Follicular Lymphoma (FL) Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Guangzhou 7 Beijing 4 Wuhan 3 Changsha 3 Shanghai 2
Narrow the registerReset
Recruitment status
Phase
Site location
Guangzhou7 Beijing4 Wuhan3 Changsha3 Shanghai2
All 19 locations
Target enrolment
to

Follicular Lymphoma (FL) trials in China

13 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Sonrotoclax, Zanubrutinib and Rituximab in Previously Untreated Patients With Follicular Lymphoma
NCT07550855Follicular Lymphoma (FL)
Sun Yat-sen University
Phase 2
52
Guangzhou
2026-09-01
Recruiting
A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies
NCT07609862Mantle Cell Lymphoma (MCL), Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma ( FL), Waldenstrรถm Macroglobulinemia (WM)
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 1/2
92
Tianjin
2026-07-14
Recruiting
A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / Refractory Non Hodgkin Lymphoma
NCT07548697B-cell Non Hodgkin Lymphoma (NHL), DLBCL - Diffuse Large B Cell Lymphoma, Follicular Lymphoma (FL)
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase EARLY_PHASE1
24
Wuhan
2026-04-30
Not yet open
Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma
NCT07168291Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma ( FL), Burkitt Lymphoma
First Affiliated Hospital Xi'an Jiaotong University
Phase EARLY_PHASE1
3
Xi'an
2025-12-31
Recruiting
Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma
NCT07077512Large B Cell Diffuse Lymphoma, Mantle Cell Lymphoma (MCL), Follicular Lymphoma ( FL)
Sun Yat-sen University
Phase 2
30
Guangzhou
2025-09-15
Not yet open
Efficacy and Safety of Zuberitamab Combined with Bendamustine, Followed by Monotherapy Maintenance, in Treatment-naรฏve Follicular Lymphoma
NCT06757894Follicular Lymphoma (FL)
Sun Yat-sen University
Phase 2
50
Guangzhou
2025-02-01
Recruiting
Zanubrutinib Combined With G-CVP in Previously Untreated FL
NCT06959732Follicular Lymphoma ( FL)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
40
Beijing
2025-01-01
Recruiting
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
NCT06526793B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL)
AstraZeneca
Phase 2
270
Chengdu, Guangzhou, Nanchang, Nanjing, Nantong, Shandong, Shanghai, Tianjin
2024-11-27
Active, closed
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma
NCT05409066Follicular Lymphoma (FL)
Genmab
Phase 3
549
Beijing, Fuzhou, Xiamen, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Changsha
2022-09-20
Recruiting
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
NCT03460977Metastatic Castration Resistant Prostate Cancer (mCRPC), Small Cell Lung Cancer (SCLC), Follicular Lymphoma (FL)
Pfizer
Phase 1
453
Guangzhou, Changsha, Nanjing, Chengdu, Wenzhou
2018-04-17
Rows per page Showing 1–13 of 13
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/condition/follicular-lymphoma-fl

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 13 of those studies listing the condition Follicular Lymphoma (FL).

How many Follicular Lymphoma (FL) trials are recruiting in China?

7 of the 13 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 4 have not yet opened recruitment, 2 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Follicular Lymphoma (FL)), 13 studies
PhaseStudiesRecruitingShare
Phase 25338.5%
Phase 34130.8%
Phase EARLY_PHASE12115.4%
Phase 1117.7%
Phase 1/2117.7%

Most active sponsors

Lead sponsors with the most studies (Follicular Lymphoma (FL))
Lead sponsorStudiesRecruiting
Sun Yat-sen University31
Genmab20
AstraZeneca11
Cancer Institute and Hospital, Chinese Academy of Medical Sciences11
First Affiliated Hospital Xi'an Jiaotong University10
Guangzhou Lupeng Pharmaceutical Company LTD.11
Pfizer11
Ruijin Hospital10
Sinocelltech Ltd.11
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.